Compass Pathways PLC (NASDAQ:CMPS) is among the best psychedelic stocks to buy in 2026. Its flagship psychedelic drug ...

LONDON, March 28, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...

The average one-year price target for COMPASS Pathways plc - Depositary Receipt (NasdaqGS:CMPS) has been revised to $23.77 / ...

Results of COMPASS Pathways’ open-label study of COMP360 psilocybin treatment, alongside SSRI antidepressants, suggest that SSRIs do not interfere with the potential therapeutic effect of COMP360 The ...

COMP360 is the first classic psychedelic1 to consistently achieve a highly statistically significant result and clinically ...

LONDON, April 29, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...

Shares of Compass Pathways fell after the company recorded a wider-than-expected fourth-quarter loss. Shares were down 3.3% to $5.17 in Tuesday morning trading. The stock is up 66% over the past year.

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today ...

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...

See what Compass Pathways’ Phase 3 COMP360 TRD data showed, why the stock jumped, and how a discounted offering reshapes the near-term setup.

Compass Pathways plc (CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the ...